PDLLA Biostimulators: Uses, Safety and Product Selection

PDLLA, or poly-D,L-lactic acid, is a biodegradable collagen biostimulator used in injectable aesthetic treatments. Unlike hyaluronic acid (HA), which is primarily used for immediate and reversible volume, PDLLA is designed to support gradual collagen remodeling over the months that follow treatment.

PDLLA is not limited to one product category. Larger or differently engineered microspheres may be used in dermal fillers for volume and wrinkle improvement, while smaller-particle PDLLA can be placed in the mid-dermis as a skin booster to address firmness, laxity, and skin quality rather than volume. The same polymer can therefore serve different clinical objectives when its particle size, concentration, carrier, and injection protocol are appropriately matched to the indication.

This guide explains what PDLLA is, how it works, where it is used, what the clinical evidence shows, how it compares with PLLA and HA, and how clinics and distributors can assess products and choose an appropriate supplier.

Key takeaways

• PDLLA is a biodegradable copolymer of D- and L-lactic acid with an amorphous structure — flexible, resistant to brittle fracture, and tunable at the formulation stage.
• It works as both a filler and a collagen biostimulator, and small-particle PDLLA is also used as a skin booster.
• In the nasolabial-fold indication, a randomized, evaluator-blinded multicenter trial reported noninferior efficacy compared with HA, while a 2026 split-face human study found no significant difference in wrinkle-severity outcomes between PDLLA and PLLA. [6,7]
• PDLLA's amorphous structure gives manufacturers room to tailor microsphere size and formulation to different treatment goals, from facial volume and wrinkle improvement to skin-quality applications.

What Is PDLLA?

PDLLA (poly-D,L-lactic acid) is a synthetic, biodegradable polymer from the polylactic acid (PLA) family. It is made by polymerizing lactic acid monomers — a mixture of the D- and L-stereoisomers — and that stereochemistry is what determines how the polymer behaves.

Because PDLLA mixes both stereoisomers, its polymer chains cannot pack into ordered crystalline regions, so the material is amorphous rather than semi-crystalline. For clinicians this is a design advantage, not a defect. Without rigid crystalline regions the polymer is more flexible and more resistant to brittle fracture, which suits dynamic facial tissue; and manufacturers have more freedom to engineer microsphere size, porosity, surface structure, and degradation behavior for a specific treatment objective. [1,2]

Two products that both say "PDLLA" can therefore behave quite differently — microsphere uniformity, controlled manufacturing, and a protocol matched to the indication are what separate them.

How it degrades

PDLLA degrades by hydrolysis into lactic acid, a molecule the body already produces and metabolizes. Polylactic-acid materials have a long history in medical devices — absorbable sutures, orthopedic implants, drug-delivery systems — which is one reason the polymer is regarded as well characterized. How fast it degrades depends on molecular weight, D/L ratio, particle architecture, and formulation. [1]

How Does PDLLA Work?

PDLLA-based products work differently from primarily volumizing fillers such as HA. They still occupy space at the time of injection, but they are also designed to trigger a tissue response that produces the patient's own collagen.

Immediate support. The carrier — commonly carboxymethylcellulose sodium (CMC) and HA — and the microspheres provide initial structural support. Part of that early effect reflects the carrier and the injected volume, which is why it should not be read as newly formed collagen.

Controlled tissue response. The body processes the microspheres through a localized, controlled response. Good microsphere design keeps that response productive rather than excessive. [1,10]

Fibroblast activation. Preclinical research suggests PDLLA can influence macrophage activity and support fibroblast activation, contributing to extracellular-matrix remodeling. [3]

Collagen regeneration. In preclinical models, PDLLA has been associated with type I and III collagen and elastin synthesis. As the microspheres gradually degrade, the new matrix integrates into the tissue rather than being metabolized away. [1,3,4,5]

Results build gradually: product-specific studies typically evaluate visible improvement from roughly 4–12 weeks, with the full effect developing over subsequent months. That course is the point — PDLLA suits patients and protocols aiming at progressive collagen regeneration, and complements rather than competes with immediate volumizers. [1,6]

PDLLA vs PLLA and HA

The three materials are often presented as competitors. In practice they answer different questions, and a well-run clinic stocks more than one.

PDLLA vs PLLA. PLLA is semi-crystalline and has the longer clinical history. Comparative studies have reported differences between specific PLLA and PDLLA formulations in aggregation behavior and early collagen expression, while a 2026 split-face human study in the nasolabial fold found no significant difference in wrinkle-severity outcomes between the two. [7,13,14] The practical message: microsphere integrity, dispersion, and a matched protocol influence outcomes more than the polymer label does.

PDLLA vs HA. HA is immediate and can be dissolved with hyaluronidase. PDLLA builds gradually and has no equivalent enzymatic reversal agent — a genuine clinical consideration that belongs in informed consent, and one reason many clinics use both: HA for instant correction and precision, PDLLA for progressive regeneration. [1,6]

What the Clinical Evidence Shows

An important randomized, evaluator-blinded, multicenter study (n = 260) compared an injectable PDLLA product with an HA comparator for nasolabial fold augmentation, with 52 weeks of follow-up. At 24 weeks, 67.6% of patients in the PDLLA group achieved at least a one-grade improvement on the Wrinkle Severity Rating Scale, versus 60.9% in the HA group — establishing noninferiority to HA. The study also reported a favorable tolerability profile over the follow-up period. [6]

That study evaluated one specific product in one indication. As with any product-specific clinical study, its findings should be interpreted in the context of the formulation, treatment area, protocol, and follow-up period rather than applied uniformly to every PDLLA product.

Clinical Applications and Indications

Applications depend on particle size, concentration, injection depth, and the approved indication in each market.

• Facial volume and wrinkles. Mid-face and cheek volume, temples, nasolabial folds, perioral lines, and chin or jawline definition are the best-documented uses, typically with 25–50 μm microspheres placed in the deep dermis or subcutaneously.
• Skin quality. Smaller microspheres placed in the mid-dermis are used to improve laxity and collagen loss — a regenerative skin-booster approach rather than a volumizing one.
• Body volume. Some products carry body indications in some markets, using larger microspheres and higher active content.
• Combination protocols. PDLLA has been used alongside HA, PRP, and energy-based devices; evidence for specific combinations varies. [1,9]

Regulatory note for distributors: body contouring is a regulated and, in some markets, restricted category. In the United States, the FDA has not approved dermal fillers for body contouring or enhancement, and specifically advises against their use for buttock or breast enhancement; other markets differ. Confirm the approved indication in writing before promoting any such use.

Safety and Tolerability

Injectable PDLLA has an established safety profile. In the randomized multicenter trial described above, the product was assessed as safe and well tolerated over 52 weeks of follow-up. [6] The most commonly reported effects — edema, bruising, erythema, and local discomfort — are transient and normally resolve without intervention.

Less common localized reactions have also been reported. Their frequency varies between studies because definitions, products, techniques, and follow-up periods differ; reported outcomes are closely tied to microsphere uniformity, reconstitution concentration, injection layer, and volume per point. [10,11,12]

Outcomes track closely with product quality and technique — which is why uniform microspheres, reproducible reconstitution, and product-specific training are central to a good result. [1,9]

The Beatrice PDLLA Platform

Beatrice is the medical-aesthetics brand of the Changzhou Institute of Materia Medica Co., Ltd. (CIMM), founded in 1984 and one of China's earliest developers of medical-grade sodium hyaluronate. More than 40 years of injectable-biomaterials work sit behind the platform, supported by 9 PhDs, 60+ patents, an independent postdoctoral research station, a long-running research partnership with Germany's NMI (University of Tübingen), and ISO 13485, ISO 9001, MDSAP, and CE certification.

Two proprietary processes define the platform:

• EQUISPHERE emulsification — designed to improve microsphere uniformity and support consistent particle distribution and predictable collagen stimulation.
• Rapid-reconstitution lyophilization — the Revive formulation reconstitutes in approximately 3–5 minutes with sterile water for injection, reducing preparation time and variability.

The material itself is amorphous PDLLA. Compared with PLLA and PCL microspheres, the amorphous structure is more flexible and more resistant to brittle fracture, which supports adaptation to dynamic facial tissue movement.

Beatrice PDLLA in clinical solutions

Rather than treating each product as a standalone item, Beatrice's Clinical Solutions framework organizes treatment planning around the patient's objective and treatment depth. The following examples show where PDLLA may fit within that broader logic; specific treatment decisions should follow the current product labeling and instructions for use.

• Targeted mesotherapy and skin quality. The framework uses dermal-level combinations to address hydration, laxity, firmness, texture, and barrier recovery. Beatrice Revive is the platform's smaller-particle PDLLA skin-booster example for mid-dermal protocols, where its indication and local labeling permit.
• Volume restoration and wrinkle correction. The framework combines immediate filling with longer-term collagen regeneration for patients with volume loss, folds, or reduced tissue support. Beatrice Restore is positioned for facial volume restoration and wrinkle improvement within this type of treatment objective.
• Higher-capacity applications. Beatrice Reshape is positioned for larger-area body volume restoration and contour remodeling where authorized. These uses are especially market-specific and should be assessed against local approvals before promotion.

This application-based view explains why product selection should begin with the treatment objective, tissue plane, particle design, and permitted combination strategy — not with the product name alone. View Beatrice Clinical Solutions.

Our internal clinical evaluation found that 81.52% of treated participants met the study's predefined effectiveness criteria at 12 months for moderate-to-severe nasolabial fold wrinkles. This result is available as data on file; qualified partners can request the study design and sample size for further review alongside the peer-reviewed evidence.

For distributors and clinics: Request the PDLLA technical data package — specification sheets, product-specific clinical data, safety documentation, reconstitution and injection protocols. → Request technical documentation

Frequently Asked Questions

What is a PDLLA filler?
An injectable product containing poly-D,L-lactic acid microspheres in a carrier. It provides an early physical effect and is intended to support gradual collagen remodeling.

How does PDLLA stimulate collagen?
Preclinical studies suggest the microspheres influence macrophage and fibroblast activity, contributing to extracellular-matrix and collagen remodeling. Magnitude and timing depend on the formulation and protocol. [3]

What is the difference between PDLLA and PLLA fillers?
PLLA is semi-crystalline and made only from L-lactic acid; PDLLA is amorphous, more flexible, and more tunable during formulation. See the comparison above.

How is PDLLA different from hyaluronic acid filler?
HA is immediate and reversible with hyaluronidase; PDLLA is gradual and has no equivalent enzymatic reversal agent. The two are complementary, and many clinics stock both.

Are PDLLA fillers safe?
Injectable PDLLA has an established safety profile. The randomized multicenter trial in the nasolabial fold reported favorable tolerability over 52 weeks, with transient swelling, bruising, and discomfort among the commonly reported effects. Outcomes depend on the product, indication, technique, and practitioner training. [1,6,10,11,12]

How should a clinic or distributor choose a PDLLA supplier?
A thorough supplier review should cover particle-size distribution, active content, carrier, reconstitution profile, product-specific clinical and safety data, GMP / ISO documentation, approved indications by market, batch-consistency data, training, and lead times.

Partner with Beatrice

We support distributors and clinics with regulatory documentation for market entry (CE / EU MDR, ANVISA, Southeast Asia and others), Beatrice Academy clinical training, OEM / ODM and private-label programs, and long-term supply.

Become a distributor

Enquiries are for healthcare professionals and trade partners only.

Disclaimer

This article is intended for healthcare professionals and industry partners. It is provided for educational purposes and does not constitute medical advice. Product availability, indications, and regulatory status vary by market; always refer to the approved labeling and instructions for use in your jurisdiction. Individual treatment results vary. The 81.52% figure comes from our internal clinical evaluation and is available as data on file.

References

1. Lee KWA, et al. Poly-d,l-lactic Acid (PDLLA) Application in Dermatology: A Literature Review. Polymers. 2024;16(18):2583. https://pmc.ncbi.nlm.nih.gov/articles/PMC11434839
2. Su CY, Chang YC, Cheng PJ, Fang HW. Comparative Physicochemical Characterization of Polylactic Acid-Based Dermal Fillers. Polymers. 2026;18(1):84. https://doi.org/10.3390/polym18010084
3. Oh S, et al. Poly-D,L-Lactic Acid Filler Increases Extracellular Matrix by Modulating Macrophages and Adipose-Derived Stem Cells in Aged Animal Skin. Antioxidants. 2023;12(6):1204. https://doi.org/10.3390/antiox12061204
4. Oh S, et al. Poly-D,L-Lactic Acid Stimulates Angiogenesis and Collagen Synthesis in Aged Animal Skin. International Journal of Molecular Sciences. 2023;24(9):7986. https://doi.org/10.3390/ijms24097986
5. Stein P, Vitavska O, Kind P, Hoppe W, Wieczorek H, Schürer NY. The biological basis for poly-L-lactic acid-induced augmentation. Journal of Dermatological Science. 2015;78(1):26–33. https://pubmed.ncbi.nlm.nih.gov/25703057
6. Ting W, et al. A Randomized, Evaluator-Blinded, Multicenter Study to Compare Injectable Poly-D,L-Lactic Acid vs Hyaluronic Acid for Nasolabial Fold Augmentation. Aesthetic Surgery Journal. 2024. https://doi.org/10.1093/asj/sjae180 · https://pubmed.ncbi.nlm.nih.gov/39178357
7. Park JY, et al. A Split Face Study Comparing the Effect of a PDLLA Based Product and PLLA on the Nasolabial Fold (NLF). Skin Research and Technology. 2026;32(1). https://doi.org/10.1111/srt.70324 · https://pubmed.ncbi.nlm.nih.gov/41532837
8. Fisher SM, Borab Z, Weir D, Rohrich RJ. The emerging role of biostimulators as an adjunct in facial rejuvenation: A systematic review. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2024;92:118–129. https://doi.org/10.1016/j.bjps.2024.02.024
9. Tam E, Choo JPS, Rao P, Webb WR, Carruthers JDA, Rahman E. A Systematic Review on the Effectiveness and Safety of Combining Biostimulators with Botulinum Toxin, Dermal Fillers, and Energy-Based Devices. Aesthetic Plastic Surgery. 2025. https://doi.org/10.1007/s00266-024-04627-5 · https://pubmed.ncbi.nlm.nih.gov/39719485
10. Perez Willis KM, Ramirez Galvez R. Granuloma after the Injection of Poly-D,L-Lactic Acid (PDLLA) Treated with Triamcinolone. Case Reports in Dermatological Medicine. 2024;2024:6544506. https://doi.org/10.1155/2024/6544506
11. Magacho-Vieira FN, et al. Clinical Management of Poly-D,L-Lactic Acid Nodules: A Guideline With Diagnostic and Treatment Flowchart. Journal of Cosmetic Dermatology. 2025. https://doi.org/10.1111/jocd.70158
12. Vleggaar D, Fitzgerald R, Lorenc ZP. Understanding, Avoiding, and Treating Potential Adverse Events Following the Use of Injectable Poly-L-Lactic Acid for Facial and Nonfacial Volumization. Journal of Drugs in Dermatology. 2014;13(suppl 4):s35–s39. https://jddonline.com/articles/understanding-avoiding-and-treating-potential-adverse-events-following-the-use-of-injectable-poly-l-S1545961614S0035X
13. Huang JCC, et al. Comparative analysis of collagen-stimulating effects of poly-L-lactic acid, poly-D,L-lactic acid, and polycaprolactone subcutaneous injections in a porcine model. Dermatologica Sinica. 2025;43(4):352–353. https://doi.org/10.4103/ds.ds-d-24-00168
14. Jang J, Jin C, et al. PLLA and PDLLA Fillers: Linking Crystallinity and Mechanical Stability to Aggregation, Redispersion, and Collagen Formation. In Vivo. 2026;40(3):1437. https://iv.iiarjournals.org/content/40/3/1437